Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2015

View Archived Issues

GPR37L1 mutation provides insight for novel inherited neurological disorder

Study of sASD markers in Taiwanese population provides new data

Novel approach studied for diagnosis and treatment of DRD

Novel mutation in a deubiquitinating enzyme related to Diamond Blackfan anemia

Phase I study begins for MVA-BN Filo/AdVac preventive Ebola vaccine regimen

Advaxis seeks FDA clearance to study ADXS-HER2 in HER2-expressing solid tumors

Lion Biotechnologies files IND for phase II study of tumor-infiltrating lymphocytes in melanoma

FDA responds to Cesca's IDE application for pivotal critical limb ischemia trial

Kite Pharma to generate CAR T cell therapies against Amgen cancer targets

Kowa divulges insulin secretagogues

Taisho Pharmaceutical reports development of GlyT-1 inhibitors

Seikagaku reports new cathepsin K inhibitors

CSIPI patents novel platinum complexes

Janssen discloses new BACE1/2 inhibitors

European phase III trial of INTERCEPT blood system meets primary endpoint

cCAM Biotherapeutics cleared to begin phase I trial of CM-24 for cancer

SGX-94 reduces pancytopenia in animal model of macrophage activation syndrome

Alkermes reports topline results from phase III study of ALKS-5461 for major depressive disorder

Dignity Sciences anti-fibrotic shows potential in mouse model of NASH

Versartis reports data from ongoing extension study of VRS-317 for growth hormone deficiency

Pfizer's acquires Redvax

KaloBios reports topline data for phase II study of KB001-A

Novartis receives approval in Canada for Fluad Pediatric

Cipher Pharmaceuticals acquires Canadian commercialization rights to ozenoxacin

Gilead Sciences acquires Phenex Pharmaceuticals' FXR liver disease programs

FDA grants SGX-301 fast track designation for cutaneous T-cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...